Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CorMedix (CRMD) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for CorMedix (CRMD) over the last 14 years, with Q3 2025 value amounting to $108.5 million.

  • CorMedix's Net Income towards Common Stockholders rose 400119.92% to $108.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $164.5 million, marking a year-over-year increase of 49985.95%. This contributed to the annual value of -$17.9 million for FY2024, which is 6252.03% up from last year.
  • CorMedix's Net Income towards Common Stockholders amounted to $108.5 million in Q3 2025, which was up 400119.92% from $21.9 million recorded in Q2 2025.
  • In the past 5 years, CorMedix's Net Income towards Common Stockholders registered a high of $108.5 million during Q3 2025, and its lowest value of -$14.5 million during Q1 2024.
  • For the 5-year period, CorMedix's Net Income towards Common Stockholders averaged around $6.3 million, with its median value being $908979.0 (2021).
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first plummeted by 25096.04% in 2023, then surged by 400119.92% in 2025.
  • CorMedix's Net Income towards Common Stockholders (Quarter) stood at -$7.8 million in 2021, then fell by 5.36% to -$8.2 million in 2022, then dropped by 18.7% to -$9.7 million in 2023, then skyrocketed by 238.18% to $13.5 million in 2024, then skyrocketed by 706.07% to $108.5 million in 2025.
  • Its last three reported values are $108.5 million in Q3 2025, $21.9 million for Q2 2025, and $20.6 million during Q1 2025.